Recently, it has been demonstrated that cobimetinib and trametinib could potentiate cancer immunotherapy by upregulating tumor antigen expression and presentation [79], promoting the production of IL-8 and VEGF, and enhancing the recruitment of immune cells to the tumor site [80]. This evidence concerns the gene VEGFA and neoplasm.